Genelux Says First Patient Dosed In US-Based Phase 2 Trial Evaluating Systemically Delivered Olvi-Vec In Patients With Recurrent Non-small Cell Lung Cancer; Interim Readout Expected Mid-2025
Portfolio Pulse from Benzinga Newsdesk
Genelux has initiated a Phase 2 trial in the US to evaluate the efficacy and safety of Olvi-Vec in combination with other treatments for recurrent non-small cell lung cancer. An interim readout is expected by mid-2025.
October 22, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genelux has dosed the first patient in a US-based Phase 2 trial for Olvi-Vec, targeting recurrent non-small cell lung cancer. The trial will compare Olvi-Vec with standard treatments, with interim results expected by mid-2025.
The initiation of a Phase 2 trial is a significant step in drug development, potentially leading to positive investor sentiment. The interim readout in mid-2025 could provide critical data influencing the stock price. The trial's focus on a prevalent cancer type adds importance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100